The frequencies of mutated alleles of CYP2D6 gene in a Turkish population

Serin, Ayşe; Canan, Husniye; Alper, Behnan; Gülmen, Mete Korkut

doi:10.1016/j.forsciint.2012.07.012

Cited by 16 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The homozygous CYP2D6*3 allele is known to generally have a low frequency in populations. Serin et al [21] reported a CYP2D6*3 genotype frequency of 1%, whereas the same genotype was not detected in a study conducted by Aynacioglu et al [13,21]. The percentage of individuals with the PM phenotype in Turkey is reported to be 1.49% [13].…”

Section: Discussionmentioning

confidence: 95%

“…The PM phenotype has previously been reported as 0-2%, 1-10%, and 1-2% in Asian, Caucasian, and African populations, respectively; the most frequently observed variant was CYP2D6*4, which induces the PM phenotype in Caucasian populations [19]. In two individual studies conducted in Turkish populations, the CYP2D6*4 homozygous variant genotype frequencies were 4% and 3% [20,21]. Similar to these studies, the CYP2D6*4 homozygous variant genotype frequency was found to be 3.6% in our study.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

Atasayar

Eryılmaz

Karlı

et al. 2016

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

Atasayar

Eryılmaz

Karlı

et al. 2016

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…CYP2D6*5 has deletion of the entire gene and is present at a similar frequency of approximately 5 % in all populations (Daly et al 1996;Lovlie et al 1996). Serin et al (2012) showed that allele frequencies of CYP2D6*3, CYP2D6*6 and CYP2D6*5 were 1, 2.5 and 3 %, respectively, in the Turkish population. In our study, CYP2D6*6 (after CYP2D6*1-normal form-allele frequency: 0.55) was the most frequent allele, with an allele frequency of 0.225.…”

Section: Discussionmentioning

confidence: 96%

“…Another study showed that CYP2D6*4 homozygous mutation rate was 4 % and allele frequency was 0.21 in a Turkish population (Koseler et al 2007). A recent study found that the allele frequency of CYP2D6*4 (1934 G [ A) was 10 % (Serin et al 2012).…”

Section: Discussionmentioning

confidence: 98%

The CYP4502D6 4 and 6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients

Yalçıntepe

Özdemir

Silan

et al. 2015

Eur J Drug Metab Pharmacokinet

View full text Add to dashboard Cite

The cytochrome P450 2D6 (CYP2D6) is a cytochrome P450 enzyme involved in the oxidative biotransformation of the xenobiotics, carcinogens and various clinically important drugs. Patients are evaluated in three sub-groups of extensive (EM), intermediate (IM) and poor metabolizer (PM) phenotypes due to their drug-metabolising ability for the target CYP2D6 gene. Colchicine non-responsive FMF patients were prospectively genotyped for the major CYP2D6 alleles in the current study. Major CYP2D6 alleles of *1, *3, *4, *5, and *6 were genotyped for 30 responsive and 60 non-responsive FMF patients by multiplex PCR-based reverse-hybridization StripAssay and real-time PCR methods. DNA banks isolated from blood-EDTA were retrospectively used in the current patients and results were compared statistically. Increased CYP2D6 *4 and *6 allele frequencies were highly detected in the colchicine non-responsive FMF patients when compared to the responsive group. Results showed the frequencies of major CYP2D6 *1(wild), *3(2637A > delA), *4(G1934A), *5(total gene deletion) and *6(1707T del) alleles in 0.550, 0.042, 0.158, 0.025 and 0.225 for non-responder and 0.880 and 0.120 (CYP2D6*1 and *4) for the responder groups, respectively. Despite small sample size, this study suggests that there is an association between CYP2D6*4 and CYP2D6*6 alleles and drug intoxicants in colchicine non-responder FMF patients.

show abstract

“…CYP2D6* 1934A allele was presented 1.38% in Koreans (28), 20.7% in Caucasians (43), 5-10% in white population (21). Also, the frequency of allele *4 was reported 0% in African, Chinese, Japan, and Mexican populations, 0.6% in Japan, 17.5-20.7% in German populations (43)(44)(45)(46)(47) and 10% and 11% in Turkish population, respectively (31,48,49).…”

Section: Discussionmentioning

confidence: 99%

Prevalence ofCYP2D6*4 1934G/A polymorphism in Western IndianHIVpatients

Singh

Lata

Gangakhedkar

2018

APMIS

View full text Add to dashboard Cite

Hepatic CYP2D6 enzyme metabolizes antiretroviral drugs (ARVs) including nevirapine. Polymorphism in CYP2D6 gene affects drug metabolism and displays distinctive phenotypes in the population. Hence, we investigated the prevalence of CYP2D6*4 1934G/A polymorphism in a total of 165 HIV patients that include 34 with and 131 without hepatotoxicity and 160 unrelated healthy controls by the PCR‐RFLP method. The prevalence of CYP2D6*4 1934AA genotype was higher in total HIV patients as compared to healthy controls (1.81% vs 0.6%, OR = 2.86). Similarly, CYP2D6*4 1934AA genotype was much more prevalent in HIV patients without hepatotoxicity as compared to healthy controls (2.3% vs 0.6%, OR = 2.87). Likewise, CYP2D6*4 1934AA genotype was predominant in advanced HIV disease stage as compared to healthy controls (3.8% vs 0.6%, OR = 6.15). CYP2D6*4 1934GA genotype was distributed higher in HIV patients taking tobacco and nevirapine as compared to non‐users (23.3% vs 19.3%, OR = 1.21, 21.0% vs 16.7%, OR = 1.2). Likewise, CYP2D6*4 1934GA genotype was overrepresented in patients with hepatotoxicity taking alcohol + nevirapine as compared to alcohol non‐users + nevirapine users (20.00% vs 16.67%, OR = 1.25). Thus, there was no significant difference in genotype or allele frequencies of CYP2D6*4 1934G/A polymorphism between the patients with hepatotoxicity and those without or healthy controls.

show abstract

The frequencies of mutated alleles of CYP2D6 gene in a Turkish population

Cited by 16 publications

References 29 publications

Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

The CYP4502D6 4 and 6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients

Prevalence ofCYP2D6*4 1934G/A polymorphism in Western IndianHIVpatients

Contact Info

Product

Resources

About

The frequencies of mutated alleles of CYP2D6 gene in a Turkish population

Cited by 16 publications

References 29 publications

Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

Association of MDR1 , CYP2D6 , and CYP2C19 gene polymorphisms with prophylactic migraine treatment response

The CYP4502D6 *4 and *6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients

Prevalence ofCYP2D6*4 1934G/A polymorphism in Western IndianHIVpatients

Contact Info

Product

Resources

About

The CYP4502D6 4 and 6 alleles are the molecular genetic markers for drug response: implications in colchicine non-responder FMF patients